| 000 | 01669 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517155048.0 | ||
| 264 | 0 | _c20180319 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1537-4513 | ||
| 024 | 7 |
_a10.1097/CJI.0000000000000173 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLeonardi, Giulia C | |
| 245 | 0 | 0 |
_aDiabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. _h[electronic resource] |
| 260 |
_bJournal of immunotherapy (Hagerstown, Md. : 1997) _c |
||
| 300 |
_a249-251 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aAutoantibodies _xblood |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Ketoacidosis _xdiagnosis |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xdiagnosis |
| 650 | 0 | 4 |
_aGlutamate Decarboxylase _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aInsulin _xtherapeutic use |
| 650 | 0 | 4 |
_aLung Neoplasms _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _ximmunology |
| 650 | 0 | 4 | _aRemission Induction |
| 700 | 1 | _aOxnard, Geoffrey R | |
| 700 | 1 | _aHaas, Andrea | |
| 700 | 1 | _aLang, Joshua P | |
| 700 | 1 | _aWilliams, Jonathan S | |
| 700 | 1 | _aAwad, Mark M | |
| 773 | 0 |
_tJournal of immunotherapy (Hagerstown, Md. : 1997) _gvol. 40 _gno. 6 _gp. 249-251 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/CJI.0000000000000173 _zAvailable from publisher's website |
| 999 |
_c27222933 _d27222933 |
||